9 5 7 4 9
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
lncRNA CASC2 在恶性肿瘤预后中的作用：一项综合分析和生物信息学
Authors Yu L, Chen S, Bao H, Zhang W, Liao M, Liang Q, Cheng X
Received 21 February 2018
Accepted for publication 22 May 2018
Published 25 July 2018 Volume 2018:11 Pages 4355—4365
DOI https://doi.org/10.2147/OTT.S166132
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Background: Cancer
susceptibility candidate 2 (CASC2) is characterized as a tumor suppressor,
which was first identified to be downregulated in endometrial carcinoma.
Accumulating evidence was provided to testify the function of CASC2 in
malignant tumors. However, a systematic and quantitative assessment is not
available. The present study was designed to evaluate the role of CASC2 in
multiple carcinomas through meta-analysis and bioinformatics.
Materials and methods: A systematic assessment of the relationship of CASC2 with tumors was performed by using several computerized databases from inception to December 1, 2017. Pooled HR with 95% CI was calculated to summarize the effect. The data on prognosis of malignant tumors were also downloaded from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database.
Results: A total of 13 studies with 966 cancer patients were pooled in the analysis to evaluate the prognostic value of CASC2 in multiple tumors and the clinical features. The results of the meta-analysis revealed that low expression levels of CASC2 were associated with poor overall survival (OS) (pooled HR=0.39, 95% CI: 0.28–0.53, P <0.0001). CASC2 obviously has a negative correlation with advanced tumor node metastasis (TNM) stage, lymph node metastasis (LNM) and T stage, respectively (P <0.05). There was, however, no significant difference in gender, distant metastasis and high differentiation (P >0.05). In the Kaplan–Meier curves with log-rank analysis, higher expression of CASC2 was positively correlated with longer survival time than patients with a lower level (P <0.05), including kidney renal clear cell carcinoma, brain lower grade glioma, pancreatic adenocarcinoma and sarcoma.
Conclusion: Findings from this meta-analysis suggest that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as advanced TNM, LNM and T stage. Data from the bioinformatics analysis revealed that higher expression of CASC2 was related to longer OS in patients with malignant tumors.
Keywords: CASC2, malignant tumors, prognosis, meta-analysis, bioinformatics
Materials and methods: A systematic assessment of the relationship of CASC2 with tumors was performed by using several computerized databases from inception to December 1, 2017. Pooled HR with 95% CI was calculated to summarize the effect. The data on prognosis of malignant tumors were also downloaded from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database.
Results: A total of 13 studies with 966 cancer patients were pooled in the analysis to evaluate the prognostic value of CASC2 in multiple tumors and the clinical features. The results of the meta-analysis revealed that low expression levels of CASC2 were associated with poor overall survival (OS) (pooled HR=0.39, 95% CI: 0.28–0.53, P <0.0001). CASC2 obviously has a negative correlation with advanced tumor node metastasis (TNM) stage, lymph node metastasis (LNM) and T stage, respectively (P <0.05). There was, however, no significant difference in gender, distant metastasis and high differentiation (P >0.05). In the Kaplan–Meier curves with log-rank analysis, higher expression of CASC2 was positively correlated with longer survival time than patients with a lower level (P <0.05), including kidney renal clear cell carcinoma, brain lower grade glioma, pancreatic adenocarcinoma and sarcoma.
Conclusion: Findings from this meta-analysis suggest that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as advanced TNM, LNM and T stage. Data from the bioinformatics analysis revealed that higher expression of CASC2 was related to longer OS in patients with malignant tumors.
Keywords: CASC2, malignant tumors, prognosis, meta-analysis, bioinformatics
